前列腺癌正电子显像剂的临床研究及应用进展  

Progress of positron imaging agents in prostate cancer

作　　者：张宝平 孙洪赞[1] 郭启勇[1] Zhang Baoping;Sun Hongzan;Guo Qiyong(Department of Radiology,Shengjing Hospital of China Medical University,Liaoning Shenyang 110004,China)

机构地区：[1]中国医科大学附属盛京医院放射科,辽宁沈阳110004

出　　处：《现代肿瘤医学》2019年第11期2013-2018,共6页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(编号:81771893;81471718)

摘　　要：PET/CT及PET/MR近年来已被应用于前列腺癌的临床检测。通过应用不同的显像剂,PET/CT及PET/MR可以评估前列腺癌的糖代谢、脂质代谢、受体变化等生物学改变,在前列腺癌的诊断、指导治疗及预后评估等方面相对于常规检测手段有独特的优势和良好的效果。近年来,许多新的放射性标记物不断被引入临床,给前列腺癌的诊断及治疗带来更广阔的应用前景。本文主要对前列腺癌正电子显像剂的临床研究及应用进展进行综述。PET/CT and PET/MR have been applied to the clinical detection of prostate cancer in recent years.They can evaluate the biological changes such as glucose metabolism,lipid metabolism and receptor changes in prostate cancer by using different positron imaging agents,which brings PET/CT and PET/MR unique advantages in the diagnosis,evaluation and prognosis evaluation of prostate cancer compared with conventional imaging methods.The clinical application of many new radiotracers in recent years have brought a breakthrough and broader application foreground for PET/CT and PET/MR in the diagnosis of prostate cancer.This article mainly reviews the clinical research and application progress of positron imaging agents in prostate cancer.

关 键 词：PET/MR PET 前列腺癌 影像学 显像剂 

分 类 号：R737.25[医药卫生—肿瘤]